This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Pertinax Therapeutics

Drug Names(s): CTCE-9908

Description: CTCE-9908 is an analog of SDF-1 and antagonist of SDF-1 receptor. CTCE-9908 inhibits function of chemokine SDF-1 (stromal cell-derived factor 1), a target involved in the cancer cells' ability to migrate and adhere to other tissues, a process known as cancer metastasis.

Deal Structure: On an undisclosed date, Pertinax Therapeutics acquired PTX-9908, formerly known as CTCE-9908.

Chemokine and University of British Columbia
In September 1999, Chemokine entered into a license agreement with The University of British Columbia (UBC) in which the UBC license granted Chemokine exclusive worldwide rights to research, develop and commercialize certain patented technologies, which remain the property of UBC.

The licensed technology relates to therapeutics involving stromal cell-derived factor 1, or SDF-1, peptide antagonists and agonists which are currently applicable to Chemokines drug candidates CTCE-9908 and CTCE-0214, respectively.

In May 2007, Chemokine announced that it has amended certain terms of its license agreement with UBC. Under the terms of the license agreement with UBC, Chemokine was required to meet milestones and make milestone payments for certain technologies related to CTCE-9908 or CTCE-0214. The amendments to the...See full deal structure in Biomedtracker

Partners: MicroConstants, Inc. TCM Biotech International Corp

PTX-9908 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug